These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23142194)

  • 21. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
    Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug.
    Glenthoj A; Glenthoj BY; Mackeprang T; Pagsberg AK; Hemmingsen RP; Jernigan TL; Baaré WF
    Psychiatry Res; 2007 Apr; 154(3):199-208. PubMed ID: 17360162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
    Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
    Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.
    Matosin N; Fernandez-Enright F; Lum JS; Andrews JL; Engel M; Huang XF; Newell KA
    Schizophr Res; 2015 Aug; 166(1-3):212-8. PubMed ID: 26048293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication.
    Hutcheson NL; Clark DG; Bolding MS; White DM; Lahti AC
    Psychiatry Res; 2014 Jan; 221(1):6-12. PubMed ID: 24210948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for onset of antipsychotic effects within the first 24 hours of treatment.
    Kapur S; Arenovich T; Agid O; Zipursky R; Lindborg S; Jones B
    Am J Psychiatry; 2005 May; 162(5):939-46. PubMed ID: 15863796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
    Crespo-Facorro B; Roiz-Santiáñez R; Pérez-Iglesias R; Pelayo-Terán JM; Rodríguez-Sánchez JM; Tordesillas-Gutiérrez D; Ramírez M; Martínez O; Gutiérrez A; de Lucas EM; Vázquez-Barquero JL
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1936-43. PubMed ID: 18930104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Volume and shape analysis of subcortical brain structures and ventricles in euthymic bipolar I disorder.
    Quigley SJ; Scanlon C; Kilmartin L; Emsell L; Langan C; Hallahan B; Murray M; Waters C; Waldron M; Hehir S; Casey H; McDermott E; Ridge J; Kenney J; O'Donoghue S; Nannery R; Ambati S; McCarthy P; Barker GJ; Cannon DM; McDonald C
    Psychiatry Res; 2015 Sep; 233(3):324-30. PubMed ID: 26254541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
    García-Cabeza I; Gómez JC; Sacristán JA; Edgell E; González de Chavez M
    BMC Psychiatry; 2001; 1():7. PubMed ID: 11835695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
    Krakowski MI; Czobor P; Nolan KA
    J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia.
    Lahti AC; Weiler MA; Medoff DR; Tamminga CA; Holcomb HH
    Psychiatry Res; 2005 May; 139(1):19-30. PubMed ID: 15950442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.
    Detke HC; Zhao F; Witte MM
    BMC Psychiatry; 2012 May; 12():51. PubMed ID: 22646847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
    Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
    Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
    J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.